CASE STUDY

Clinical-stage biopharmaceutical company

The Challenge

This clinical-stage biopharmaceutical company’s chemistry engine combined in-house medicinal chemistry design with external synthesis capabilities. It was critical for them to have a robust process for tracking the design cycle (Design-Make-Test-Analyze) to assure expedient execution and quality decision making.

A specific technical challenge, common to many institutions, is unambiguous tracking of synthetic targets across multiple projects and partners. Issues may and do arise from keeping track of the target status, changes in the target priority, and other synthetic queue modifications.

The solution

While solutions to these common problems exist at large pharma companies, and are typically proprietary, the selection of tools for smaller biotech companies is limited.

We heard about chemTraX (now Torx Make) from one of our partners and were excited to give it a try. It turned out to be a tool which met many of our needs: unambiguous tracking of synthetic targets across multiple projects/CRO partners, flexible customization to meet our project objectives, and ease of implementation.

Among other benefits, it should be mentioned that the implementation team were very attentive and responsive to our needs. Robust control of access privileges for CRO partners was implemented natively within the application.

Director of Chemistry, clinical-stage biopharmaceutical company

The Results

The company now has an accessible and unambiguous system for synthetic target tracking which eliminates target duplication and ambiguity, greatly simplifies management of multiple chemistry CRO partners, and provides an up-to-date status of the synthetic queue.

We are excited about the prospect of further integration of this tool in our chemistry workflow.

Director of Chemistry, clinical-stage biopharmaceutical company

Case study: Clinical-stage biopharmaceutical company

Your DMTA cycle needs Torx®

Request an evaluation